ProCE Banner Activity

ExpressPoints: Current and Future Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Slideset Download
Download this short summary slideset of key takeaway points on using immune checkpoint inhibitors for patients with gastroesophageal cancers.

Released: August 10, 2020

Expiration: August 09, 2021

No longer available for credit.

Share

Faculty

Manish A. Shah

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Zev A. Wainberg

Zev A. Wainberg, MD

Co-Director, GI Oncology Program
Professor of Medicine and Surgery
Director, Early Phase Therapeutics
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Manish A. Shah, MD

Assistant Member, Department of Medicine, Gastrointestinal Oncology
Memorial Sloan-Kettering Cancer Center
Attending Physician, Department of Medicine, Division of Solidy Tumor Oncology
Memorial Hospital
New York, New York

Zev A. Wainberg, MD

Co-Director, GI Oncology Program
Professor of Medicine and Surgery
Director, Early Phase Therapeutics
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California